Product-led growth for B2B SaaS founders for healthcare and life sciences in Southern Europe

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Southern Europe. In this market, Southern European buyers reward relationship depth over transactional outreach, so the way you install product-led growth has to be shaped to that reality from day one.

If you are a B2B SaaS founder still under $5m ARR, product-led growth is not something you delegate on day one. It is using product usage — not a rep — as the primary lead source, and until it works you cannot describe your business without hand-waving.

The founder value in product-led growth is that CAC collapses when the product qualifies for you. You bring context no hire can replicate — the reason you started the company, the exact objection you heard on call number seven, the phrase a customer used that finally clicked.

Own the strategy, the first 30 live cycles, and the weekly review. Delegate the tooling, the list building, and the reporting. Founders who invert that order end up hiring around a broken model.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Southern Europe it is compounded by the fact that relationship depth, not activity volume is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Instrument self-serve activation to paid conversion from day one — even if the number is embarrassing. You cannot debug what you do not measure, and every board meeting after Series A will start with this chart.

The founder trap in product-led growth is bolting PLG onto a product that requires a demo to understand. It always looks reasonable at the time. Write the trap on a sticky note and stick it on your monitor.

The moment to hand off product-led growth is when you can predict the number two weeks out and defend the assumptions behind it. Not before. VP hires that arrive earlier tend to leave inside 14 months.

Founders who take product-led growth seriously in year one write category-defining companies in year three. The compounding is that stark.

Concretely for healthcare and life sciences in Southern Europe: the healthcare teams that install this get past procurement instead of dying in it, and a single trusted Southern European relationship compounds into a regional beachhead. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.